NASDAQ:BMRABiomerica Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.22 -0.26 (-3.07 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$7.99Now: $8.22▼$8.4850-Day Range$7.25MA: $8.88▼$12.0452-Week Range$2.05Now: $8.22▼$23.39Volume499,851 shsAverage Volume1.07 million shsMarket Capitalization$96.61 millionP/E RatioN/ADividend YieldN/ABeta-0.71 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily offers its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the point-of-care and in-hospital/clinical laboratories worldwide. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy, which is in clinical studies to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingBiomerica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Biomerica has a potential upside of 33.8% from its current price of $8.22.Amount of Analyst CoverageBiomerica has received no research coverage in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesBiomerica has received 125 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBiomerica has received 130 “underperform” votes. (Add your “underperform” vote.)Community SentimentBiomerica has received 50.98% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Biomerica and other stocks. Vote “Outperform” if you believe BMRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMRA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBiomerica does not currently pay a dividend.Dividend GrowthBiomerica does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biomerica insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 25.70% of the stock of Biomerica is held by insiders.Percentage Held by InstitutionsOnly 5.19% of the stock of Biomerica is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biomerica are expected to grow in the coming year, from ($0.25) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomerica is -30.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomerica is -30.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomerica has a P/B Ratio of 20.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.33 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Dental equipment & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BMRA Previous Symbol CUSIPN/A CIK73290 Webwww.biomerica.com Phone949-645-2111Debt Debt-to-Equity Ratio0.35 Current Ratio3.00 Quick Ratio1.86Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.20 million Price / Sales18.58 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book20.05Profitability EPS (Most Recent Fiscal Year)($0.26) Net Income$-2,390,000.00 Net Margins-51.37% Return on Equity-67.54% Return on Assets-38.75%Miscellaneous Employees54 Outstanding Shares11,753,000Market Cap$96.61 million Next Earnings Date9/4/2020 (Estimated) OptionableNot Optionable $8.22 -0.26 (-3.07 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BMRA News and Ratings via Email Sign-up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Biomerica (NASDAQ:BMRA) Frequently Asked Questions How has Biomerica's stock price been impacted by Coronavirus? Biomerica's stock was trading at $2.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BMRA stock has increased by 183.4% and is now trading at $8.22. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Biomerica? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biomerica. When is Biomerica's next earnings date? Biomerica is scheduled to release its next quarterly earnings announcement on Friday, September 4th 2020. View our earnings forecast for Biomerica. How were Biomerica's earnings last quarter? Biomerica, Inc. (NASDAQ:BMRA) released its quarterly earnings results on Tuesday, April, 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.03. The business earned $1.18 million during the quarter, compared to analyst estimates of $1.35 million. Biomerica had a negative net margin of 51.37% and a negative return on equity of 67.54%. View Biomerica's earnings history. What price target have analysts set for BMRA? 1 analysts have issued 12-month target prices for Biomerica's shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate Biomerica's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 33.8% from the stock's current price. View analysts' price targets for Biomerica. Has Biomerica been receiving favorable news coverage? News stories about BMRA stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Biomerica earned a news impact score of -1.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Biomerica. Are investors shorting Biomerica? Biomerica saw a drop in short interest in April. As of April 30th, there was short interest totaling 209,600 shares, a drop of 53.7% from the April 15th total of 452,500 shares. Based on an average daily trading volume, of 1,710,000 shares, the short-interest ratio is presently 0.1 days. Approximately 2.5% of the shares of the company are short sold. View Biomerica's Short Interest. Who are some of Biomerica's key competitors? Some companies that are related to Biomerica include Straumann (SAUHF), Sartorius (SARTF), DENTSPLY SIRONA (XRAY), SmileDirectClub (SDC), BIOLASE (BIOL) and Remedent (REMI). View all competitors. What other stocks do shareholders of Biomerica own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Opko Health (OPK), Pfizer (PFE), T2 Biosystems (TTOO), Veru (VERU), Akers Biosciences (AKER), Blink Charging (BLNK), Co-Diagnostics (CODX) and Vuzix (VUZI). Who are Biomerica's key executives? Biomerica's management team includes the following people: Mr. Zackary S. Irani, Chairman & CEO (Age 53)Ms. Janet Moore, CFO, Treasurer, Sec. & Director (Age 68) What is Biomerica's stock symbol? Biomerica trades on the NASDAQ under the ticker symbol "BMRA." Who are Biomerica's major shareholders? Biomerica's stock is owned by many different institutional and retail investors. Top institutional shareholders include Heritage Investors Management Corp (0.58%), Perritt Capital Management Inc. (0.21%), Virtu Financial LLC (0.19%) and California Public Employees Retirement System (0.13%). View institutional ownership trends for Biomerica. Which institutional investors are selling Biomerica stock? BMRA stock was sold by a variety of institutional investors in the last quarter, including Perritt Capital Management Inc.. View insider buying and selling activity for Biomerica. Which institutional investors are buying Biomerica stock? BMRA stock was purchased by a variety of institutional investors in the last quarter, including Heritage Investors Management Corp, Virtu Financial LLC, and California Public Employees Retirement System. View insider buying and selling activity for Biomerica. How do I buy shares of Biomerica? Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Biomerica's stock price today? One share of BMRA stock can currently be purchased for approximately $8.22. How big of a company is Biomerica? Biomerica has a market capitalization of $96.61 million and generates $5.20 million in revenue each year. The company earns $-2,390,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. Biomerica employs 54 workers across the globe. What is Biomerica's official website? The official website for Biomerica is www.biomerica.com. How can I contact Biomerica? Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at 949-645-2111. This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
